Cartesian Therapeutics, Inc. RNAC announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis (MG), an ...

Cartesian Therapeutics, Inc. (RNAC) shares soared 9.9% in the last trading session to close at $13.39. The move was backed by solid volume with far more shares changing hands than in a normal session.

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase 3 crucial. Click here to read more on RNAC.

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis ...

16:13 EST Cartesian Therapeutics (RNAC) files to sell 6.25M shares of common stock for holdersPick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked analysts ...

Selecta and Cartesian are merging, adding roughly $60 million via a private placement to help advance a suite of auto-immune-targeted cell therapies.

Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, today announced that the U.S. Securi ...

It believes extrapolating from Cartesian’s Phase 2, Descartes-08 would likely need six additional infusions to show a similar benefit. The Uplizna study “muddies” commercial outlook for ...